The EMCDDA provide updated guidance to policy-makers and public health providers on developing strategies to prevent and control the spread of blood-borne infections among people who inject drugs.
The Lancet underscores the futility and harms of drug criminalisation, pointing to the growing evidence supporting decriminalisation and the expansion of harm reduction services.
The Robert Carr Fund's innovative grant-making model contributes to the empowerment of organizations engaged in HIV response through long-term funding, flexible core funding, and deliberate efforts towards shifting power to civil society.
The Global Commission on Drug Policy calls for an end to the criminalisation and neglect experienced by people who use drugs and fueling these global pandemics, urging for the scale-up of services and recognition of community leadership.
The Working Group on Women, Drug Policy and Incarceration reflects on almost ten years of collective research and joint advocacy, achievements and disappointments, as well as challenges and opportunities for the future.
The CSFD urges EU institutions to safeguard human rights commitments and call for an immediate ceasefire, ensuring that humanitarian aid includes access to controlled medicines and the continuity of drug services.
Transform Drug Policy Foundation look beyond the use of psychedelics solely for therapeutic use, examining how to shape policy and regulation for psychedelics outside the medical sphere.
Harm Reduction International highlight key debates, decisions and documents in which drug control and its impact on human rights were analysed and addressed at the 54th session of the Human Rights Council.
The Centre on Drug Policy Evaluation outlines how social responsibility and equity can be enhanced within Canadian cannabis legislation, emphasising the inclusion of underrepresented racialised people and genders, reparations for the harms of cannabis prohibition through reinvestment of taxes, and amnesty for previous cannabis convictions.
